Extended Lymphadenectomy Does Not Improve DFS or OS Among Patients with Localised Muscle Invasive Bladder Cancer By Ogkologos - November 4, 2024 1942 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SWOG S1011 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR How to Cope With Panic Attacks During Cancer July 12, 2022 Zenocutuzumab Shows Efficacy in Patients with Advanced NRG1 Fusion-positive Cancers February 19, 2025 T-DM1 Approval Expanded to Include Some Women with Early-Stage HER2-Positive Breast... May 23, 2019 Immunotherapy after Surgery Shows Long-Term Benefits for High-Risk Bladder Cancer March 21, 2023 Load more HOT NEWS FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole... Hormone Therapy for Prostate Cancer? A Genetic Test Could Help Decide Tarlatamab Shows Promise in Patients with Previously Treated Small-Cell Lung Cancer What Is Intuitive Eating and How Can It Help During Cancer?
